Fresenius braves plunging markets with €1bn trade
Fresenius, the German healthcare company, pushed ahead with a €1bn dual tranche no-grow trade on Monday, despite an issuer in another sector pulling its deal as wider markets plummeted.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: